Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemigliptin in T2DM with Renal Impairment (GUARD)
NCT01968044Phase 3Completed
- Sponsor
- LG Chem
- Start
- Oct 2013
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gemigliptin in type 2 diabetes mellitus (T2DM), sponsored by LG Chem. Started Oct 2013; status: completed.
02
Drugs
gemigliptin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01968044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01968044.